{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:09:43Z","timestamp":1794712183370,"version":"4.9.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This retrospective analysis aimed to provide evidence-based risk stratification of TP53-mutated (TP53mut) myeloid neoplasms (MNs). Of 580 MNs harboring TP53mut with variant allele frequency (VAF) \u22652%, 219 (37.8%), 194 (33.4%), 92 (15.9%), and 75 (12.9%) were classified as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) with low blasts (MDS-LB), MDS with excess blasts (MDS-EB)-2, and -EB1 according to the revised fourth edition of the World Health Organization (WHO) classification, respectively. Hierarchical analysis identified the following 4 risk groups with distinct survival: (1) MDS-LB, (2) MDS-EB1\/EB2\/AML VAF &amp;lt;10%, (3) MDS-EB1\/EB2 VAF \u226510%, and (4) AML VAF \u226510%. We next evaluated the impact of allelic status, VAF, and complex karyotype (CK). In our cohort, the significance of biallelic status was limited to MDS with &amp;lt;5% blasts and not for blasts 5% to 9%, as proposed by the International Consensus Classification (ICC), or 5% to 19%, as proposed by the fifth edition of the WHO (WHO-5). MDS-EB1 and -EB2 with VAF \u226510% had comparable survival (9.6 vs 7.2 months; P = .12), regardless of allelic status. Contrary to the ICC proposal, MDS-EB1\/EB2 with VAF &amp;lt;10% and CK had poor survival compared with those without CK, comparable to MDS-EB1\/EB2 with VAF \u226510% (5.6 vs 26.2 vs 6.3 months; P = .003). Survival of TP53mut AML was poor (median 3.9 months) regardless of allelic\/CK status. Thus, using ICC or WHO-5 may underestimate prognosis of MDS with blasts 5% to 19% and 5% to 9%, respectively. Collectively, the hierarchical model acknowledges poor survival of 91.9% TP53mut MDS and AML compared with 36.5% and 80.7% by WHO-5 and ICC, respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015238","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T18:27:36Z","timestamp":1741976856000},"page":"3370-3380","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Evidence-based risk stratification of myeloid neoplasms harboring\n                    <i>TP53<\/i>\n                    mutations"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun Vinod","family":"Shah","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9354-5864","authenticated-orcid":false,"given":"Kevin","family":"Hung","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-0489","authenticated-orcid":false,"given":"Anmol","family":"Baranwal","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-091X","authenticated-orcid":false,"given":"Monika M.","family":"Kutyna","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia"},{"name":"3Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6414-6441","authenticated-orcid":false,"given":"Carla","family":"Toop","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia"},{"name":"4Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-9011","authenticated-orcid":false,"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-0138","authenticated-orcid":false,"given":"Anna","family":"Brown","sequence":"additional","affiliation":[{"name":"6Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia"},{"name":"7Department of Genetic and Molecular Pathogy, SA Pathology, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Shah","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Khanna","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Ladon","sequence":"additional","affiliation":[{"name":"7Department of Genetic and Molecular Pathogy, SA Pathology, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedavyas","family":"Gannamani","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede","family":"Begna","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe K.","family":"Price","sequence":"additional","affiliation":[{"name":"3Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia"},{"name":"4Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Rud","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bardy","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"8Department of Hematology\/Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-9814","authenticated-orcid":false,"given":"Sharad","family":"Kumar","sequence":"additional","affiliation":[{"name":"6Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia"},{"name":"4Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[{"name":"9Hematology\/Oncology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-8163","authenticated-orcid":false,"given":"Rong","family":"He","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-631X","authenticated-orcid":false,"given":"Hamish S.","family":"Scott","sequence":"additional","affiliation":[{"name":"6Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia"},{"name":"7Department of Genetic and Molecular Pathogy, SA Pathology, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5420-3514","authenticated-orcid":false,"given":"Cecilia Y.","family":"Arana Yi","sequence":"additional","affiliation":[{"name":"8Department of Hematology\/Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Alkhateeb","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thomas","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia"},{"name":"3Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia"},{"name":"4Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-2554","authenticated-orcid":false,"given":"Christopher N.","family":"Hahn","sequence":"additional","affiliation":[{"name":"6Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia"},{"name":"7Department of Genetic and Molecular Pathogy, SA Pathology, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"10Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2160-9689","authenticated-orcid":false,"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[{"name":"11Department of Pathology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-7852","authenticated-orcid":false,"given":"Chung Hoow","family":"Kok","sequence":"additional","affiliation":[{"name":"3Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia"},{"name":"6Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia"},{"name":"7Department of Genetic and Molecular Pathogy, SA Pathology, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-3056","authenticated-orcid":false,"given":"Devendra","family":"Hiwase","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia"},{"name":"3Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia"},{"name":"4Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"6Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"6","key":"2025070811220117100_bib1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2025070811220117100_bib2","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"18","key":"2025070811220117100_bib3","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","article-title":"Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2025070811220117100_bib4","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2025070811220117100_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"2025070811220117100_bib6","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"23","key":"2025070811220117100_bib7","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2025070811220117100_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"issue":"22","key":"2025070811220117100_bib9","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"issue":"12","key":"2025070811220117100_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/gcc.22796","article-title":"The role of TP53 in acute myeloid leukemia: challenges and opportunities","volume":"58","author":"Barbosa","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2025070811220117100_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.hoc.2019.11.004","article-title":"Targeting TP53 mutations in myelodysplastic syndromes","volume":"34","author":"Hunter","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"2025070811220117100_bib12","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2025070811220117100_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood.2022018236","article-title":"TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype","volume":"141","author":"Hiwase","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025070811220117100_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41408-023-00821-x","article-title":"TP53 mutation variant allele frequency of \u226510% is associated with poor prognosis in therapy-related myeloid neoplasms","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J"},{"issue":"15","key":"2025070811220117100_bib15","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025070811220117100_bib16","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2025070811220117100_bib17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2025070811220117100_bib18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2025070811220117100_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/bloodadvances.2024014140","article-title":"Diagnosis of TP53-mutated myeloid disease by the ICC and WHO 5th Edition Classifications","volume":"9","author":"Hart","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025070811220117100_bib20","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood-2023-187860","article-title":"Comparison of World Health Organization and International Consensus Classification guidelines for myeloid neoplasms harboring TP53-mutations using an independent international cohort","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2025070811220117100_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"issue":"3","key":"2025070811220117100_bib22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2025070811220117100_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","article-title":"Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia","volume":"16","author":"Bahaj","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025070811220117100_bib24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: how can we improve outcomes?","author":"Sallman","year":"5  2024","journal-title":"Blood"},{"issue":"22","key":"2025070811220117100_bib25","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3370\/2401775\/blooda_adv-2024-015238-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3370\/2401775\/blooda_adv-2024-015238-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T11:22:13Z","timestamp":1751973733000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/13\/3370\/536044\/Evidence-based-risk-stratification-of-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015238","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,8]]},"published":{"date-parts":[[2025,7,8]]}}}